Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study

Date: 
June, 2017

May 18, 2017. This retrospective, matched, multinational claims analysis (N=309,056) was conducted to determine whether real-world data confirmed clinical trial findings of decreased rates of cardiovascular (CV) death and hospitalization for heart failure (HHF) in patients using sodium glucose co-transporter-2 (SGLT-2) inhibitor drugs. All patients had type 2 diabetes and atherosclerotic CV disease; propensity matching was used to compare patients using SGLT-2 inhibitors vs other glucose-lowering agents. Of patients receiving SGLT-2 inhibitors, the majority were taking canagliflozin (53%) or dapagliflozin (42%); 5% received empagliflozin. Investigators found that the use of SGLT-2 inhibitors was associated with lower rates of CV death (hazard ratio [HR] 0.49; 95% CI 0.41-0.57; P<0.001) and HHF (HR 0.61; 95% CI 0.51-0.73; P<0.001). These findings strengthen the argument for a potential CV disease class effect of SGLT-2 inhibitors.